Citi lowered the firm’s price target on Arcus Biosciences to $37 from $44 and keeps a Buy rating on the shares. The analyst updated biotechnology models to reflect reported Q4 and 2023 financials.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.